NO20074254L - Krystallinsk og amorf 4-cyano-N[(2R)-2-[4-(2,3-dihydro-benzo[1,4]dioksin-5-yl)-piperazin-1-yl]-propyl)-N-pyridin-2-yl-benzamid-hydroklorid - Google Patents

Krystallinsk og amorf 4-cyano-N[(2R)-2-[4-(2,3-dihydro-benzo[1,4]dioksin-5-yl)-piperazin-1-yl]-propyl)-N-pyridin-2-yl-benzamid-hydroklorid

Info

Publication number
NO20074254L
NO20074254L NO20074254A NO20074254A NO20074254L NO 20074254 L NO20074254 L NO 20074254L NO 20074254 A NO20074254 A NO 20074254A NO 20074254 A NO20074254 A NO 20074254A NO 20074254 L NO20074254 L NO 20074254L
Authority
NO
Norway
Prior art keywords
dioxin
piperazin
benzo
dihydro
cyano
Prior art date
Application number
NO20074254A
Other languages
English (en)
Inventor
Anthony Francis Hadfield
Michel Bernatchez
Mark Lankau
Eric N C Browne
Abdolsamad Tadayon
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20074254L publication Critical patent/NO20074254L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

(I) Foreliggende oppfinnelse omhandler krystallinske og amorfe former av 5-HT1A reseptorantagonisten 4-cyano-N-{(2R)-2-[4-(2,3-dihydro-benzo[1,4]dioksin-5-yl)-piperazin-1-yl]-propyl}-N-pyridin-2-yl-benzamidhydroklorid, så vel som sammensetninger derav og fremgangsmåter for anvendelse av disse. ?? ?? ?? ?? 38
NO20074254A 2005-03-01 2007-08-21 Krystallinsk og amorf 4-cyano-N[(2R)-2-[4-(2,3-dihydro-benzo[1,4]dioksin-5-yl)-piperazin-1-yl]-propyl)-N-pyridin-2-yl-benzamid-hydroklorid NO20074254L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65757505P 2005-03-01 2005-03-01
PCT/US2006/006802 WO2006093853A1 (en) 2005-03-01 2006-02-27 Crystalline and amorphous 4-cyano-n{(2r)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-n-pyridin-2-yl-benzamide hydrochloride

Publications (1)

Publication Number Publication Date
NO20074254L true NO20074254L (no) 2007-09-24

Family

ID=36659970

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074254A NO20074254L (no) 2005-03-01 2007-08-21 Krystallinsk og amorf 4-cyano-N[(2R)-2-[4-(2,3-dihydro-benzo[1,4]dioksin-5-yl)-piperazin-1-yl]-propyl)-N-pyridin-2-yl-benzamid-hydroklorid

Country Status (19)

Country Link
US (2) US20070027162A1 (no)
EP (1) EP1853593A1 (no)
JP (1) JP2008531694A (no)
KR (1) KR20070112797A (no)
CN (1) CN101137648A (no)
AR (1) AR053152A1 (no)
AU (1) AU2006218845A1 (no)
BR (1) BRPI0609370A2 (no)
CA (1) CA2599588A1 (no)
CR (1) CR9319A (no)
GT (1) GT200600098A (no)
IL (1) IL185267A0 (no)
MX (1) MX2007010524A (no)
NI (1) NI200700217A (no)
NO (1) NO20074254L (no)
PE (1) PE20061344A1 (no)
RU (1) RU2007131044A (no)
TW (1) TW200700413A (no)
WO (1) WO2006093853A1 (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080043855A (ko) * 2005-09-09 2008-05-19 와이어쓰 레코조탄을 포함하는 약학적 제형 및 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101722A (en) * 1991-05-02 1996-05-14 Wyeth John & Brother Ltd History of piperazine, their preparation and pharmaceutical preparations containing them
GB9125900D0 (en) * 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5568992A (en) * 1995-05-19 1996-10-29 Caterpillar Paving Products Inc. Screed control system for an asphalt paver and method of use
US5756532A (en) * 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6287839B1 (en) * 1997-11-19 2001-09-11 Genencor International, Inc. Cellulase producing actinomycetes, cellulase produced therefrom and method of producing same
US6127062A (en) * 1998-03-24 2000-10-03 Duracell Inc End cap seal assembly for an electrochemical cell
EP1112270B1 (en) * 1998-09-10 2007-03-21 F. Hoffmann-La Roche Ag Dihydrobenzodioxine carboxamide and ketone derivatives as 5-ht4 receptor antagonists
IT1318394B1 (it) * 2000-03-17 2003-08-25 Enichem Spa Processo per la preparazione di 1-esene.
US6469007B2 (en) * 2000-11-28 2002-10-22 Wyeth Serotonergic agents
US7091349B2 (en) * 2002-03-12 2006-08-15 Wyeth Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution
CN1304388C (zh) * 2002-03-12 2007-03-14 惠氏公司 合成手性n－芳基哌嗪的方法
BR0308315A (pt) * 2002-03-12 2004-12-28 Wyeth Corp Preparação de ácido n1-(2'-piridil)-1,2-propanodiamina sulfâmico e seu uso na sìntese de piperazinas biologicamente ativas
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
US20050209245A1 (en) * 2004-03-19 2005-09-22 Wyeth Process for preparing N-aryl-piperazine derivatives
TWI257220B (en) * 2005-03-25 2006-06-21 Ind Tech Res Inst Cross-layer rate adaptation mechanism for WLAN

Also Published As

Publication number Publication date
TW200700413A (en) 2007-01-01
WO2006093853A1 (en) 2006-09-08
US20090192311A1 (en) 2009-07-30
GT200600098A (es) 2006-11-09
CR9319A (es) 2008-01-21
IL185267A0 (en) 2008-02-09
JP2008531694A (ja) 2008-08-14
RU2007131044A (ru) 2009-04-10
CA2599588A1 (en) 2006-09-08
AR053152A1 (es) 2007-04-25
BRPI0609370A2 (pt) 2010-03-30
KR20070112797A (ko) 2007-11-27
CN101137648A (zh) 2008-03-05
PE20061344A1 (es) 2007-01-03
AU2006218845A1 (en) 2006-09-08
US20070027162A1 (en) 2007-02-01
MX2007010524A (es) 2008-01-16
EP1853593A1 (en) 2007-11-14
NI200700217A (es) 2008-07-24

Similar Documents

Publication Publication Date Title
DE602006007556D1 (de) Heteroarylsulfonylstilbene als 5-ht2a-antagonisten
ATE463495T1 (de) Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
NO20073663L (no) Tiazol-4-karboksamid-derivater som mGluR5 antagonister
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
NO20051260L (no) Arylsubstituerte diazabicykloalkaner som nikotinacetylcholinagonister
PE20130325A1 (es) Derivados de piperidina, piperazina o tetrahidropiridilo como antagonistas de trpv1
DK1716152T3 (da) Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser
TW200800946A (en) Substituted piperazines as metabotropic glutamate receptor antagonists
DE602005009977D1 (de) Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten
MY153719A (en) Prokineticin 1 receptor antagonists
EA200700367A1 (ru) Новые производные 4-бензилиденпиперидина
TW200716566A (en) Prokineticin 2 receptor antagonists
TR201907381T4 (tr) Beta-laktamil fenilalanin, sistein ve serin vazopressin antagonisti.
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
PA8626501A1 (es) Nuevos derivados de bencil(ideno)-lactamas
NO20082909L (no) Fremgangsmate for a utvinne lignan-ekstrakter og sammensetninger inneholdende lignan-ekstraktene
ATE393147T1 (de) Kondensierte cycloheptan- und kondensierte azacycloheptan-derivate und ihre verwendung als integrin-rezeptor-antagonisten
DE602005027870D1 (de) Cgrp-rezeptorantagonisten
ATE502936T1 (de) 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten
DE602006020450D1 (de) Ykinin-rezeptorantagonisten
CY1112449T1 (el) Υποκατεστημενα ν-βενζο [d] ισοξαζολ-3-υλ-αμινο παραγωγα ως αναστολεις υποδοχεων mglur5, σεροτονινης-(5-ητ) και νοραδρεναλινης και η χρηση αυτων για την παραγωγη φαρμακων
ATE452130T1 (de) 1-(hetero)aryl-3-aminopyrrolidinderivate zur verwendung als antagonisten des mglur3-rezeptors
RS51858B (en) 4 - [(3-FLUOROPHENOXY) PHENYLMETHYL] PIPERIDINE METANSULPHONATE: ITS USES, PROCESSING METHODS AND PHARMACEUTICAL COMPOSITIONS
ATE450503T1 (de) Pyrrolidinderivate als histamin-h3- rezeptorantagonisten
DE60327375D1 (de) Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application